-+ 0.00%
-+ 0.00%
-+ 0.00%

Corcept resubmits FDA NDA for relacorilant in Cushing’s syndrome, expects six-month review

PUBT·06/17/2026 20:28:13
Listen to the news
Corcept resubmits FDA NDA for relacorilant in Cushing’s syndrome, expects six-month review
  • Corcept resubmitted its NDA to the FDA for relacorilant to treat Cushing’s syndrome.
  • The filing includes additional analyses requested by the FDA.
  • The company expects a six-month FDA review.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Corcept Therapeutics Incorporated published the original content used to generate this news brief via Business Wire (Ref. ID: 20260617001418) on June 17, 2026, and is solely responsible for the information contained therein.